ATRIAL FIBRILLATION deep vein thrombosis pulmonary embolism
Conditions
Interventions
Group 1: Patients already taking edoxaban who have a diagnostic or therapeutic procedure will have a follow up phone call 30 days after having a procedure to see if they had any bleeding or cardiovasc
Sponsors
Daiichi Sankyo
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Patients taking edoxaban for a therapeutic indication according to the SmPC (NVAF, VTE including DVT and PE) • Paients with a planned or unplanned diagnostic or interventional procedure • Age = 18 years • Written informed consent • Availability of patients for follow-up by telephone • No concurrent participation in an interventional study
Exclusion criteria
Exclusion criteria: N/A
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Any bleeding event the patient experiences within 30 days of the procedure will be collected. This will be done by a phone call. The bleeding events are categorised according to ISTH (International Society on Thrombosis and Haemostasis) standards. | — |
Secondary
| Measure | Time frame |
|---|---|
| Any cardiovascular event the patient experiences within 30 days of the procedure will be collected. This will be done by a follow up phone call to the patient. | — |
Countries
Belgium, Germany, Italy, Netherlands, Portugal, Spain, United Kingdom
Contacts
Public ContactPetra Laeis
Daiichi Sankyo
Outcome results
None listed